Home Neuronal Signaling NMDAR antagonist Kynurenic acid For research use only.

Kynurenic acid

Synonyms: Quinurenic acid, Kynurenate

Kynurenic acid (Quinurenic acid, Kynurenate), a natural metabolite of tryptophan via the kynurenine pathway, is a broad-spectrum excitatory amino acid antagonist; It proved to be an antagonist at NMDA, kainate and AMPA receptors.

Kynurenic acid Chemical Structure

Kynurenic acid Chemical Structure

CAS: 492-27-3

Selleck's Kynurenic acid has been cited by 2 publications

Purity & Quality Control

Batch: Purity: 99.94%
99.94

Kynurenic acid Related Products

Choose Selective NMDAR Inhibitors

Biological Activity

Description Kynurenic acid (Quinurenic acid, Kynurenate), a natural metabolite of tryptophan via the kynurenine pathway, is a broad-spectrum excitatory amino acid antagonist; It proved to be an antagonist at NMDA, kainate and AMPA receptors.
Targets
α7 nicotinic acetylcholine receptor [1] glutamate receptors [2] NMDAR [4]
In vitro
In vitro Kynurenic acid(KYNA) is neuroactive tryptophan metabolites formed along the kynurenine pathway. It is considered a non-competitive antagonist of glutamate receptors of NMDA type. KYNA, at low concentration, inhibits FGF-1 release in all cellular models and displays a major stimulatory effect on the proliferation rate of mouse microglia and human glioblastoma cells, in vitro[2].
In Vivo
In vivo Treatment with KYNA (30–100 mg per kg of body weight, intravenously) 4 h before the start of heat stress significantly (P<0.05) and dose-dependently decreases the survival time to new values of 152–356 min compared with normothermic rats. KYNA protects against hypotension but not hyperthermia during heatstroke. KYNA attenuates hypothalamic neuronal degeneration and apoptosis during heatstroke. Also spleen, kidney, liver, and lung apoptosis during heatstroke are decrease. KYNA up-regulates serum IL-10 levels but down-regulates serum TNF-α and ICAM-1 levels. KYNA treatment significantly prevents the occurrence of heat-induced multi-organ damage and inflammation without affecting the induced hyperthermia. Only high doses of KYNA proved to be neuroprotective in neonatal rats by reducing anoxia or hypoxia-ischemia-induced brain edema and in adult rats and gerbils given before ischemia induction. KYNA cannot cross the blood-brain barrier[3].
Animal Research Animal Models Adult male Sprague-Dawley rats
Dosages 30-100 mg/kg
Administration i.v
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06029296 Not yet recruiting
Alcohol Use Disorder
University of Maryland Baltimore
 November 2023 Early Phase 1
NCT05488951 Recruiting
Dementia
Augusta University
 July 1 2022 Not Applicable
NCT05969990 Recruiting
Migraine in Children
Qilu Hospital of Shandong University
 January 1 2022 --
NCT05280054 Unknown status
Drug Drug Interaction
VistaGen Therapeutics Inc.|Parexel
 December 23 2021 Phase 1

Chemical Information & Solubility

Molecular Weight 189.17 Formula

C10H7NO3
CAS No. 492-27-3 SDF Download Kynurenic acid SDF
Smiles C1=CC=C2C(=C1)C(=O)C=C(N2)C(=O)O
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 19 mg/mL ( (100.43 mM)； Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Kynurenic acid | Kynurenic acid supplier | purchase Kynurenic acid | Kynurenic acid cost | Kynurenic acid manufacturer | order Kynurenic acid | Kynurenic acid distributor